Marijuana Stocks: Back to Where We Started!

0
12391

Since 2014 we have been bringing our members some of the BIGGEST gains in Marijuana Stocks! Double, Triple and Cumulative Quadruple digit gains were and are the norm.

Does this mean we are without our losses? HECK NO! No one, not even MarijuanaStocks.com is without a share of losers as well. Have we had far more wins than losses? HECK YES! Consistency is what matters and within a sector still growing and findinits stable footing, MarijuanaStocks.com has been and will continue to be a consistent rock for all who are interested in the budding cannabis Space.

With that said…we want to bring your attention to a company we have been behind since 2014!

For those that have been with us for a little while, you will surely remember OXIS International, which we have been covering on and off since 2014. On June 26th, 2017 we began to cover OXIS again. OXIS started at $0.0142 per share and went to highs of $0.029 per share for total gains of over 100%! In August 2017 OXIS, now (GTBP) began trading record volume and went from $0.017 per share to highs of $0.123!

July 17th, 2017 Oxis International changed its name to GT Biopharma Inc. (GTBP). On August 21st, 2017 OXIS International effected a reverse stock split, and on September 1st, 2017 they acquired Georgetown Translational Pharmaceuticals, Inc. September 20th, 2017 the company began trading under the ticker symbol (GTBP). The post reverse price was $18.00 per share and on August 28th, 2017 (GTBP) reached highs of $19.25.

From September 2017 to January 2018 there would be downward pressure. However, volatility in (GTBP) has historically created positive trading opportunities.

  • October 2017: 10/12/17 Low $4.11 – 10/20/17 High $7.55
  • November 2017: 11/28/17 Low $4.48 – 11/30/17 High $6.73
  • January 2018: 1/05/18 Low $4.00 – 1/10/18 High $5.85

MORE RECENTLY:

  • March/April 2018: 3/28/18 Low $1.58 – 4/2/18 High $2.25 (+42%)
  • May 2018: 5/4/18 Low $1.19 – 5/10/18 High $1.91 (+60.5%)
  • May/June 2018: 5/31/18 Low $1.37 – 6/7/18 High $2.79 (+103.6%)

As you can see the volatility in GT BIOPHARMA (GTBP) has provided investors the opportunity for positive trading, throughout this period.

On January 23rd, 2018 (GTBP) announced the closing of a $7.1m USD financing. The stock fell from $4.80 per share to a low of $2.72! Confusion! Naturally, (GTBP) shareholders were confused as we were at MarijuanaStocks.com, that (GTBP) would announce a successful financing and the stock would drop to new lows.

During the period January 2018 – the present we have been watching the price, news and corporate developments at (GTBP). (GTBP) has added an ALL-STAR management roster and received positive results on clinical trials.

(GTBP) has been on a wild ride in the past year. We believe (GTBP) has gone through an extended correction & is now ready to potentially continue moving up!

DISCLAIMER:
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Full Disclaimer Here

When investing one can never make assumptions. Investors must complete extensive due diligence before participating in the buying or selling of any security. It is important to look for proven management teams, serious scientific information and solid drug candidate development plans before investing in any biotech company.

The information in this article is historical fact and accurate stock market data. When considering investments in development stage companies as individual investors we must make certain we do not fall prey speculative, misleading or any information brazenly hyping the stock of any individual company.

LEAVE A REPLY

Please enter your comment!
Please enter your name here